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ABSTRACT 
Adverse drug reactions (ADRs) have a major impact on public health, reducing patient’s quality of life and imposing a considerable financial 
burden on the health care systems at a time when many health care systems are under considerable financial strain. All healthcare providers 
have roles to play in maintaining a balance between a medicine's benefits and risks. Once a drug is available to the public, making a 
determination about its safety is the shared responsibility of all who are part of the prescribing process, including patients. The role of 
healthcare professionals is vital in recording and reporting suspected ADRs in order that regulatory agencies are alerted of emerging safety 
concerns and thereby facilitating timely and appropriate action. Pharmacovigilance is an important exercise for monitoring of drug related 
issues after marketed in “real world setting”. Pharmacovigilance and all drug related issues are important for everyone whose life is being 
impacted any way by medical interventions. The evolution of Pharmacovigilance in recent years has growing importance as a sci ence critical 
to effective clinical practice and public health science. The national Pharmacovigilance centers have become a significant influence on the 
drug regulatory authorities, at a time when drug safety concerns have become increasingly important in public health and clinical practice. 
This paper unfolds the basics of drug safety and other important aspects of Pharmacovigilance.  
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INTRODUCTION  
Drug Post-marketing surveillance programs are essential in 
every country for monitoring the occurrence of ADRs, as the 
data derived from within the country may encourage 
national regulatory decision making. These programs may 
contribute to decrease in morbidity, mortality, hospital-
lization and healthcare costs, and liability associated with 
ADRs. Majority ADRs often go unrecognized or unreported. 
An organized ADR monitoring program is one mechanism to 
more actively detect ADRs, and consequently positively 
affect the quality of patient care 1. To prevent or lessen harm 
to patients and improving public health, the various 
mechanisms for evaluating and monitoring the safety of 
medicines in clinical use are important. In Clinical practice 
this implies having in place a well-organized Pharmaco-
vigilance system. Pharmacovigilance in the early 1990s was 
entirely about monitoring adverse drug reactions and hence 
was defined as "The detection in the community of drug 
effects, usually adverse. Pharmacovigilance may be passive 
(the collection of spontaneous reports) or active (structured) 
where patients and prescribers are recruited and surveyed" 
2, 3. The WHO defines Pharmacovigilance as the science of 
collecting, monitoring, researching, assessing and evaluating 
information from healthcare providers and patients on the 
adverse effects of medications, biological products, 
herbalism and traditional medicines with a view to 
identifying new information about hazards associated with 
medicines and preventing harm to patients4. Pharmaco 
vigilance has been elucidated as: “The science and activities 
relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related 
problem5. Pharmacovigilance is an important exercise for 
monitoring of drug related issues after marketed in “real 
world setting”. Pharmacovigilance and all drug related issues 
are important for everyone whose life is being impacted any 
way by medical interventions. The evolution of Pharmaco 
vigilance in recent years has growing importance as a 
science critical to effective clinical practice and public health 
science. The national Pharmacovigilance centers have 
become a significant influence on the drug regulatory 
authorities, at a time when drug safety concerns have 
become increasingly important in public health and clinical 
practice. Pharmacovigilance is now firmly based on strong 
scientific principles and is basis to effective clinical practice. 
The discipline needs to develop further to meet public 
expectations and the demands of modern public health 6, 7. 
Pharmacovigilance is aimed at;  
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 Improving patient care and safety in relation to the use 
of medicines and all medical and paramedical inter-
ventions,  
 Improving public health and safety in relation to the use 
of medicines,  
 Contributing to the assessment of benefit, harm, 
effectiveness and risk of medicines, encouraging their 
safe, rational and more effective (including cost 
effective) use, and  
 Promotion of understanding, education and clinical 
training in pharmacovigilance and its effective 
communication to the public 8. 
Need for Pharmacovigilance: 
Not everything is known about a medicine when it receives 
its license for marketing. The merits of a new drug, balancing 
its beneficial and its untoward effects become established 
only after sufficient experience has been gained from its use 
in real practice. The reasons for the necessity of 
Pharmacovigilance are:  
 Information on drug safety collected during drug 
development is incomplete as preclinical drug 
development processes involve the evaluation of drug 
safety and efficacy in animal experiments and often it 
may not be appropriate to extrapolate the results of 
animal experiments to human.  
 Clinical trials are evaluated for limited duration and 
limited numbers of carefully selected patients in 
carefully selected settings and so it is extremely difficult 
to accurately determine actual efficacy, adverse effects 
and total risk-benefit ratio under actual clinical setting.  
 information is often incomplete or not available on  
 Rare but serious reactions.  
 Use of drugs in vulnerable groups (pregnant women, 
children, geriatric).  
 Risks of long term, repeated use and drug-drug, drug-
food, drug-nutritional supplement interactions.  
 At the time of licensing, the drug is exposed to less than 
5,000 human subjects. This allows only the most 
common ADRs to be detected.  
 At least 30,000 people are required to be treated with a 
drug to be sure not to miss at least one patient with an 
ADR which has an incidence of 1 in 10,000 exposed 
individuals9. 
Partners in Pharmacovigilance  
Management of the issues related to the use of medicines 
demands close and effective association between the key 
stakeholders in the Pharmacovigilance. The people respon-
sible should jointly anticipate, elucidate and respond to the 
continually enhanced demands and expectations of the 
public, health administrator policy officials, politicians and 
health professionals. However, there is little prospect of this 
happening in the absence of strong and comprehensive 
systems which make such associations possible. The 
obstacles typically encompass lack of training, resources, 
political support, and especially scientific infrastructure. 
Understanding and tackling these are a necessary 
prerequisite for future development of the science and 
practice of Pharmacovigilance 10. Pharmacovigilance is the 
responsibility of everyone so that all drugs can be used 
safely. Furthermore, the Ministry of Health (MOH) or its 
equivalent in any country of the world is not only 
responsible for monitoring drug safety but also needs 
commitment and collaboration between the different 
Pharmacovigilance partners 11. 
A comprehensive list of these ‘partners’ includes:- 
1. Healthcare professionals:- 
A. Prescribers 
B. Nurses 
C. Pharmacist 
2. Patients. 
3. Hospitals and academia. 
4. Pharmaceutical Industry. 
5. The WHO Quality Assurance and Safety (Medicines 
Team). 
6. National Pharmacovigilance Centers (NPC). 
7. Uppsala Monitoring Center (UMC). 
8. Others. 
1. Healthcare professionals: 
Safe medication use is critical for physicians, dentists, 
pharmacists and nurses. They have the responsibility to be 
vigilant of their patients of any issues related with drug 
therapy including, 
a) Nature of the disease, 
b) Purpose of medication, and 
c) Any potential risks involved in its use. 
They also have an additional responsibility to ensure that 
their patients have an adequate understanding of the nature 
of the treatment(s) they are taking. 
A. Prescribers: 
It is a prerequisite that all involved in the process of 
prescribing of medicines have some knowledge of the 
potential ADRs, so that an assessment of the balance 
between the beneficial and harm is considered before a drug 
is prescribed, dispensed and administered to a patient. Any 
medication or any kind of treatment should take in 
consideration all these factors including, the individual 
patient and their predisposition to drug toxicity. The 
intention of the prescriber is to use a medicine to help the 
patient, not harm them, as they hope all drugs used are 
without any risk. This should facilitate the key recognition 
that if the patient develops any undesired signs and 
symptoms it may be drug related and eventually turn out to 
be due to an ADR 12. Therefore, all the members of the 
healthcare team are required to be aware of the importance 
of ADR reporting and that they are competent to provide 
practical information for reporting of ADRs. They should 
have a familiarity with the policy and procedures of ADRs 
reporting and guidance as to how and when to report and 
where to actually send it. 
Healthcare professionals usually consider that they have a 
major responsibility to be a Pharmacovigilance partner by 
reporting suspected ADRs. The best management of ADRs 
needs to involve all healthcare professionals in any type of 
hospital whether government or private so as to both 
observe and report unwanted or unexpected ADRs. 
Sometimes, due to inadequate information from the 
pharmaceutical company or industry or even a Food and 
Drug Administration (FDA), a healthcare professional cannot 
always be blamed if a patient has an ADR especially so, if it is 
of an idiosyncratic type where its prediction is clearly 
impossible. But, even when healthcare professionals have 
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enough safety information they may misuse it due to not 
having the patient's full medical history and that can lead to 
ADRs. A good example is Spironolactone which is contraindi-
cated in patients with renal dysfunction or hyperkalemia. 
However, some doctors are not aware of this well reported 
effect and yet still prescribe it 13. 
B. Nurses 
Traditionally nurses did not report ADRs. But some new 
developments for ADRs reporting have taken place for 
nurses and as they are now also able to prescribe drugs in 
some countries such as USA and the UK as such prescribers 
they have the responsibility to report ADRs.  For example, in 
the UK, some nurses after October 2002 played a valuable 
part in the improvement of Pharmacovigilance by ADRs 
reporting 14, 15. A little later, in the Sweden, nurses could 
report ADRs and so contributed to the improvement of 
public health by the detection of suspected ADRs; 16. 
Currently, the contribution of nurses to the rate of reporting 
in some countries is quite significant, for example, Sweden 
12%, Canada 16% and in the UK 21%. In contrast, the 
spontaneous nurse reporting in the Italian database is still 
lower than that in other countries.  It is quite clear that 
nurses do represent an important and valuable source of 
reporting for ADRs17. 
C. Pharmacist 
A pharmacist, in a dispenser of medicines, is in a 
"cornerstone position”, he/she should be fully aware of any 
suspected ADRs. The pharmacist specifically focuses in 
making a contribution to ADR reporting. 
2. Patients 
In 2005, the reporting system for suspected ADRs by 
patients to the regulatory authorities started in the UK via 
using YCS (yellow card system). In 2009, ADRs reporting by 
patients in the UK, Sweden, Australia and the USA were in 
the range of 18% to 20%, submitted using three major 
methods: postal, internet and telephone to provide 
assessment awareness. These methods were found fitting for 
the UK‘s general population and indicated that the 
awareness was low and could be improved 18, 19, 20. 
In the study by Van Grootheest and Berg, 2004, which 
examined the role of patients in reporting ADRs, they 
concluded that, because patients have a positive value and 
involvement in drug therapy, their concern regarding 
possible adverse effects is a major factor in possible ADR 
reporting. As a consequence, patients’ reports on ADRs 
should be accepted albeit with care as is now done in the UK. 
The literature, as yet, does not provide any major results in 
relation to the detection of ADRs by patients, more recent 
studies are required to show their contribution worldwide. 
In any system where patients have taken medicines, their 
views and options about their therapy can be of great 
knowledge for ADRs reporting. It is, however, a difficult 
problem to address. Often, because of the brevity of the 
physician’s consultation process, patients have little time to 
understand any warnings that may be given about the 
potential problems of their treatment(s). It could be argued 
that the inclusion of the patient's information leaflet should 
avoid such difficulties. However, this applies to people whose 
first language is English and, when they are used in Saudi 
Arabia, where many people who use the medicine do not 
read a high level of English, their value is very difficult if not 
impossible to assess. On the other hand, in a study by Hughes 
et al. (2002) ADRs reporting by patients was not considered 
by Pharmacovigilance centers to be equivalent to those of 
the health care professionals as many of ADRs patient 
reports were incorrectly filled in, so increasing the overall 
workload for little gain 21. Another study by Arson et.al 
(2011) concluded that direct patient reporting through the 
YCS is viewed as important by those who have used the 
scheme, in order to provide the patient experience for the 
benefit of Pharmacovigilance, as an independent perspective 
from those of health professionals. 
3. Hospital and Academia 
Collaborations between the pharmaceutical industry, 
academia and drug regulatory authorities has led to the 
development of Pharmacovigilance as a clinical discipline. 
Only a small number of medical institutions provide medical 
student education related to ADR during their curricula in 
pharmacology. So, the majority of healthcare professionals 
may graduate without an adequate background regarding 
drug ADRs. Therefore, academic centers of pharmacology 
and pharmacy should provide a knowledge of ADRs to 
healthcare professionals and the public by; training, teaching 
and research. In many schools of health and medical 
institutions the topic is still neglected. Consequently, there is 
a still greater need for integration of Pharmacovigilance by 
clinical practice so as to affect a system for ADR monitoring 
to protect public health as suggested by WHO 10 years ago. 
4. Pharmaceutical Industry 
Every company in the pharmaceutical industry has a vital 
role to play in the provision and supervision of drug safety 
and they must inspect all drug related information, from 
drug development to patient use, and should also consider 
the assessment of the safety of the drug and monitoring 
system. An important role exists in communication between 
the pharmaceutical company and drug regulatory authority 
that leads to an improvement by exchanged information 22.  
5. The WHO Quality Assurance and Safety: Medicines 
Team 
The provision of guidance and support to countries 
regarding drug safety matters is a function of the Quality 
Assurance and Safety: Medicines Team within WHO. The 
purpose of the department is stated to be: "to help save lives 
and improve health by closing the huge gap between the 
benefit that essential drugs have to offer and the reality that 
for millions of people–particularly the poor and dis-
advantaged– medicines are unavailable, unaffordable, unsafe 
or improperly used". Clearly, the purpose of Quality 
Assurance and Safety for Medicines team is "To ensure the 
quality, safety and efficacy of all medicines by strengthening 
and putting into practice regulatory and quality assurance 
standards". Hence, Pharmacovigilance needs to be applied to 
all related health technologies, including medicines, vaccines, 
blood products, biotechnology, herbal medicines and 
traditional medicines. 
6. Uppsala Monitoring Center (UMC) 
During early 1960s, after the infamous event of ‘Thalidomide 
disaster’, various national schemes for collecting information 
concerning emerging drug hazards were implemented, and, 
in 1968, the WHO set up an international drug monitoring 
programme. 10 years later, in 1978, the UMC was started and 
was made responsible for leading and managing this 
programme. Working with the WHO Collaborating centre for 
international drug monitoring UMC, WHO promotes 
Pharmacovigilance at the country level23, and encourages the 
participation in the WHO programme for international drug 
monitoring. In addition, WHO still highlights the importance 
of collaboration and communication at local, regional and 
international levels, so as to ensure Pharmacovigilance 
delivers the necessary protection to the public. 
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In 2004, the numbers of countries that were participating in 
this scheme was 86, and all these provided the necessary 
data for the WHO programme with the collaborating centre 
in Uppsala, Sweden. This contrasts with the initial 
established national reporting system for ADRs which was 
for only 10 countries. In March 2010, the number of 
countries had grown to 97 and in addition there were a 
further 33 countries as “associate members” 24. At the end of 
2010, the number had increased to 134 countries and they 
were all part of the WHO Pharmacovigilance Program. More 
recently, In May 2012, the number now stands at 142 
countries. It can be seen that the Kingdom of Saudi Arabia 
(KSA) has been a member of the WHO IDMP since 2009. On 
30 March 2010, new information from the Uppsala 
monitoring centre website showed that the global ADR 
database they maintain for the WHO programme contains 5 
million ADR reports from all the countries who are members 
of the WHO programme. In 2011, the UMC-WHO, which 
managed the global database of Individual Case Safety 
Reports (ICSRs) and consists of reports of ADRs which were 
received from national centers in the WHO network 
database, is called "VigiBase". It currently contains over 6 
million descriptions of individual cases which make a 
significant contribution to promoting a global ADRs 
awareness. This information about ADRs is extremely useful 
and helpful as, unfortunately, many hospital admissions are 
caused by drug use. The Uppsala centre can therefore clarify 
any problems should they occur. The Uppsala center, to 
function effectively, requires constant new information 
about ADRs, where and when they occur 25. 
7. The National Pharmacovigilance Centers (NPC) 
In addition, most MOHs in their own countries can support 
Pharmacovigilance National Centers fully or at least in part 
by comparing expenditure of medication with the NPC 
policies and regulatory guidelines. In addition, The 
International Conference for Drug Regulatory (ICDRA) at 
their Annual Meetings of National Pharmacovigilance 
provides an unparalleled opportunity for the WHO 
programme for International Drug Monitoring to be 
comprehensively and adequately discussed. 
8. Others partners of Pharmacovigilance 
The media, advocacy groups, and lawyers can help in the 
contribution directly or indirectly to the creation of policies 
and legislation on Pharmacovigilance by cooperation and 
communication with the proper authorities. 
Pharmacovigilance in a country's national drug 
policy  
The provision of good quality, safe and effective medicines 
and their proper use is the responsibility of national 
governments. The set up of a National medicine regulatory 
agency and an assigned center for the study of adverse 
reactions are critical to the achievement of these functions. 
Interdisciplinary association is of prime importance, in 
particular, links need to be forged between various 
departments of the ministry of health and also with other 
stakeholders, such as the pharmaceutical industry, 
universities, nongovernmental organizations (NGOs) and 
professional associations having responsibility for education 
on rational use of medicines and pharmacotherapy 
monitoring 26. 
Methods of Pharmacovigilance  
Pharmacovigilance methods that can be employed in specific 
circumstances is based upon de the local situation, 
experience, expertise, and resources available to achieve 
these objectives  
Active surveillance  
This method depends on active follow-up of patients after 
treatment, and all adverse reactions are detected either by 
asking patients directly or by screening the patient records.  
Cohort event monitoring: Cohort studies are studies that 
identify subsets of a defined population and follow them 
over time, looking for differences in their outcome. Cohort 
studies generally are used to compare exposed patients to 
unexposed patients or one exposure to another 27.  
Cohort studies have many advantages. They are the best way 
to ascertain both the incidence and natural history of 
disorder, temporal sequence between cause and outcome is 
usually clear, useful in investigation of multiple outcomes 
that might arise after a single exposure, useful in the study of 
rare exposure. It also has some disadvantages such as 
selection bias is built into such studies, follow up can be 
difficult 28.   
Cohort event monitoring can be done with different 
epidemiological designs as follows:  
1. Observational  
This means that the studies are "non-interventional and are 
undertaken in real life situations. Patients are not selected 
according to any criteria: all patients who receive treatment 
are included until the desired cohort size is achieved. 
Patients of all ages, those with other diseases and those on 
other medicines are included in this. Treatment is given 
according to the usual local guidelines 29.  
Prospective  
This means that CEM is planned before the patients are 
treated and treatment is monitored until the end of the 
program, or until they cease to receive treatment for 
whatever reason.  
3. Inceptional  
In this every patient is followed-up for adverse events from 
the time of commencement of their treatment.  
4. Dynamic  
In this new patients are added as the study continues until 
such time as there are sufficient numbers in the cohort.  
5. Longitudinal  
In this the occurrence of any events in patients are observed 
over a period of time until the end of the programme, or until 
they cease to receive treatment with the monitored 
medicines.  
6. Descriptive  
In this all events are identified and described, their 
frequency is measured and their distribution in different 
subgroups of interest in the cohort is recorded and analyzed 
29.  
b. Sentinel Sites  
Active surveillance can be achieved by reviewing medical 
records or interviewing and/or physicians in a sample of 
sentinel sites to ensure complete and accurate data on 
reported adverse reactions from these sites. The selected 
sites can provide information, such as data from specific 
patient subgroups that would not be available in a passive 
system and information on the use of a drug can be targeted 
at sentinel sites.  
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c. Registries  
A registry is a patient list presenting with the same 
characteristics. This characteristic can be a disease (disease 
registry) or a specific drug exposure. Pregnancy is also 
recorded as an event as part of the cohort event monitoring 
study. This helps to estimate the exposure to medicines 
during pregnancy 30.  
D. Deaths  
As part of cohort event monitoring, all deaths can be 
recorded, and their causes assessed by verbal autopsy. 
Where possible the data will be cross-tabulated with data 
from governmental records of deaths. In a study done by U. 
Mehta 31, they have carried out confidential enquiry into 
malaria related deaths which proved to be useful tool for 
identifying the preventable factors ,health system failures, 
and adverse events affecting the malaria case management.  
Passive surveillance  
Passive surveillance or spontaneous reporting is reporting of 
adverse events that are entirely dependent on the initiative 
and motivation of the reporters. Spontaneous reporting is 
the most common method, easy to establish, cheapest to run, 
but reporting rates are low. In districts where active 
surveillance cannot be done due to constraints of manpower 
and funds, passive surveillance can be done by spontaneous 
reporting using National ADR reporting forms if available, 
suitably modified if necessary. Spontaneous reporting is 
dependent on clinicians and other health professionals who 
need to be trained and encouraged to report details of 
suspected adverse reactions in patients on ART treatment 32. 
CONCLUSION  
Pharmacovigilance is important for the protection of public 
health as it prevents, detects and assesses adverse reactions 
to medicinal products for human use. It encompasses whole 
life-cycle management of medicinal products for human use 
keeping safety aspect in mind. Consequently, we must stress 
on the necessity of the Pharmacovigilance as a continuation 
and completing of the analysis performed on medicines 
beginning from the clinical trials when the medication is 
administered for the first time in humans, and not only after 
they have been marketed. Pharmacovigilance continues to 
play an important role in meeting the threats posed by the 
ever increasing list of medicines, each of which carry an 
inevitable risk of unpredictable potential for harm. 
Whenever adverse effects and toxicity occur, especially when 
previously unknown, it is obligatory that these are reported, 
analyzed and their significance is communicated effectively 
to the people having knowledge to interpret the information. 
The harm can be reduced by ensuring that medicinal 
products of good quality, safety and efficacy are used 
rationally. In addition, the expectations and concerns about 
outcomes of the patient are taken into consideration when 
therapeutic decisions are taken. To obtain this goal and to 
boost a sense of trust among patients, ensure that risk in 
drug use are predicted, well manage and communicated to 
the regulatory authorities and other health care 
professionals. 
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